Study Phase 3

A Prospective, Open-Label, Comparative, Parallel Double-Arm, Multicentric Clinical Study to Evaluate the Efficacy of an Ovule With Triple Active Agents (Terconazole, Clindamycin, Fluocinolone) Administered Once Per Day for Three Days Versus an Ovule With Triple Active Agents (Metronidazole, Nystatin, Fluocinolone) Administered Once Per Day for Ten Days to Treat Secondary Vulvar/Vaginal Symptoms of Vaginitis/Infectious Vaginosis (Bacterial and/or Mycotic and/or Parasitic)

  • PDF icon for CSR Summary CSR Summary not Available
  • Globe symbol for NCT Number NCT01867164
  • Notebook for Primary Citation Primary Citation Not Yet Available
  • Spreadsheet for Data Specification Data Specification Not Available

Trial Information

Generic NameTerconazoleProduct NameTERAZOL ®Therapeutic AreaUrinary Tract, Sexual Organs, and Pregnancy ConditionsEnrollment160% FemaleN/A% WhiteN/A
Product ClassOB/GYNSponsor Protocol NumberTEROV8BAC4001Data PartnerJohnson & JohnsonCondition StudiedVaginitis Infectious VaginosisMean/Median Age (Years)N/A

Supporting Documentation

  • Statistical Analysis Plan Available
  • Clinical Study Report Available
Additional Information

Please note: individual participant-level data are not available for this trial. Only the statistical analysis plan and full clinical study report are available.


Clinical study data provided through this site do not replace the official labeling of a given drug product, which presents benefits and risks of the product for approved use(s). Before prescribing any product, health care professionals should consult the current prescribing information approved in their country. Patients seeking information may consult with their health care professional about the product, for which health authority approved written patient information may be available.